June 17, 2022
1 min watch
Save
VIDEO: MGD treatment shows short-term, long-term improvement in clinical findings
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO – Treatment with Alcon’s Systane iLux for meibomian gland dysfunction resulted in improvement in clinical findings at 2 weeks and 12 months, Shane Kannarr, OD, said at Optometry’s Meeting.
“This can greatly alter our first-line treatment for meibomian gland disease,” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Kannarr SR, et al. Thermal pulsation system in the treatment of meibomian gland dysfunction: A post-hoc analysis of a 12-month, randomized, multicenter study. Presented at: Optometry’s Meeting; June 15-18, 2022; Chicago.
Disclosures:
Disclosure: Kannarr reports being an investigator for this study.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.